-
"Chinese Pharmacopoeia" draft standards for pharmaceutical packaging materials are solicited for comments, the first round ends on September 1
Time of Update: 2022-08-15
Contact number: 010-67079620, 67079566 Attachment: List of draft standards for pharmaceutical packaging materials that have been publicly solicited for comments For details, please click [ read the original text ] to view On July 18, the official website of the State Pharmacopoeia Committee issued a notice to solicit opinions on the first batch of 46 draft standards .
-
In August, a large number of pharmaceutical companies announced that their products passed the consistency evaluation. Northeast Pharmaceuticals, Lianhuan Pharmaceuticals, etc.
Time of Update: 2022-08-15
Bihuan Pharmaceutical: Drotaverine Hydrochloride Injection was over-reviewed and won the first one On August 5, Bihuan Pharmaceutical announced that the company's Drotaverine Hydrochloride Injection has recently passed the quality and efficacy consistency evaluation of generic drugs .
-
Oseltamivir won the bid for the seventh batch of centralized procurement at 0.99 yuan per pill, and the "one product is the only one" is under pressure!
Time of Update: 2022-08-15
Both multinational and local companies must face the premium criteria for innovative products in the medical insurance payment market The industry generally believes that the centralized procurement of drugs with a large amount has brought about a fundamental change in the pharmaceutical industry.
-
The results of the seventh batch of centralized collection are released, how did Qilu "kill the madness"?
Time of Update: 2022-08-15
The King of Consistency Evaluation: Qilu's review performance As of July 12, 2022, Qilu Pharmaceutical Group has accumulatively reviewed (including deemed approved) 112 drug varieties, and has accumulated 193 approvals (see the end of the article for details), making it a leader among major companies .
-
Phase III clinical was smashed!
Time of Update: 2022-08-15
In fact, it is not uncommon for multinational pharmaceutical companies to fail in the R&D of new drugs, including Roche and Sanofi The failure of Merck's project R&D has attracted the attention of the industry.
-
Under the tide of resignation of pharmaceutical companies, executives "run away in groups" frequently!
Time of Update: 2022-08-15
On May 9, Ding Changtian applied for his resignation as a director of the company, a member of the Strategic Development and Investment Committee of the Board of Directors, and a member of the Remuneration and Assessment Committee of the Board of Directors for personal reasons; on March 11, Heavy Pharmaceutical Holdings received the resignation report of Chairman Liu Shaoyun; also in March, the company announced the resignation of Deputy General Manager and Chief Financial Officer Zhang Hong .
-
How many "dark horses" can domestic ADCs run?
Time of Update: 2022-08-15
Research and development progress of SHR-A1811, source: Hengrui Medicine 2021 Annual Report Lepu Bio has acquired a number of ADC drugs and ADC R&D platforms that are still in the early stage due to the acquisition of the controlling stake in Shanghai Meiya, and has become a leading pharmaceutical company in the domestic ADC track .
-
The threat of patent expiration goes deep!
Time of Update: 2022-08-15
. In conclusion, mergers and acquisitions or partnering with smaller biopharmaceutical companies (such as forming alliances) can help pharma companies significantly close the innovation gap they may face in the coming years .
-
The State Food and Drug Administration cancels the medical device registration certificate of Tianzhihang Medical and other enterprises
Time of Update: 2022-08-15
, On May 10, in accordance with the "Regulations on the Supervision and Administration of Medical Devices", according to the application of enterprises, the State Food and Drug Administration cancelled the registration certificates of medical devices for 6 products below 3 companies including Shenzhen Boka Biotechnology Co.
-
The highest drop is 97%!
Time of Update: 2022-08-15
, the quotation strategy is becoming more and more mature The average price of the drugs to be selected is reduced by 48%; it is the same as the special centralized procurement of insulin, but the decline is moderated compared with the first five batches of centralized procurement.
-
Notice of Postponement of "Packaging World (Shanghai) Expo"
Time of Update: 2022-08-15
Dear exhibitors, partners, audience friends, and media friends: In view of the current epidemic prevention and control policies in Shanghai and many places across the country, and at the same time to
-
The treatment of non-small cell lung cancer exceeds US$400 million to help develop differentiated EGFR inhibitors
Time of Update: 2022-08-15
Image source: Cullinan Oncology's official websiteUnder the terms of the agreement, Taiho will acquire Cullinan Pearl, which owns the global development rights for CLN-081/TAS6417 outside of Japan, and will pay Cullinan Oncology an upfront payment of $275 million, as well as regulatory milestones related to EGFR exon 20 insertion mutant NSCLC.
-
"Anti-Monopoly Law" accelerated revision!
Time of Update: 2022-08-15
On June 8, the State Administration for Market Regulation released the "Annual Report on China's Anti-monopoly Law Enforcement (2021)" (hereinafter referred to as the "Report") . The "Report" pointed
-
The medical insurance negotiation declaration is in full swing!
Time of Update: 2022-08-15
0 1 Reasonable competition and standard price Encourage horizontal comparison of products As in previous years, this year's medical insurance negotiation work is still divided into five stages: preparation, declaration, expert review, negotiation/bidding, and announcement of results .
-
Hengrui's class 1 new drug is listed on the market!
Time of Update: 2022-08-15
Domestic review and approval · new trends In this issue, CDE has 54 acceptance numbers (36 varieties) reported to update the production management status. Among them, Liaoning Haisco's Cyclopofol Inj
-
【Shichen】Enter a high-tech enterprise——Topchain Pharma/Topchain Pharma
Time of Update: 2022-08-15
sample application Microcrystalline cellulose, pellet core, co-processing Scan the code to receive samples Dongchen Pharmaceutical The company integrates research and development, production and sales, with the goal of building an internationally renowned and domestic leading modern high-tech enterprise and service provider.
-
Another pharmaceutical company has been intensively investigated by the organization!
Time of Update: 2022-08-15
. Among the blockbuster products, HP518, a new drug for the treatment of drug-resistant prostate cancer, was independently developed and successfully promoted to enter Phase I clinical trials in Australia, and achieved the first patient administration (FIH).
-
Priority introduction and price exposure, the new crown neutralizing antibody welcomes the highlight moment?
Time of Update: 2022-08-15
3 New crown neutralizing antibody research and development is hot More than 30 domestic enterprises are deployed According to incomplete statistics, there are 7 types of COVID-19 neutralizing antibody therapies on the market globally, namely Casirizumab + Idezumab from Roche and Regeneron, and Atelizumab + Banivirumab from Eli Lilly.
-
The seventh batch of national arrows is on the line, in-depth analysis of the competition pattern of pharmaceutical companies
Time of Update: 2022-08-15
The rules are basically mature and steadily advancing After three years and six batches of practice in the national centralized procurement, the rules are constantly improving, and a basic institutional framework for normalization and institutionalization has been formed, including three levels: First, price discovery is carried out through the national centralized procurement bidding process, and the price is bottomed out on the premise of ensuring the reasonable profits of the enterprise .
-
On the same day, there were major changes in the executives of many pharmaceutical companies
Time of Update: 2022-08-15
For example, AstraZeneca also issued an internal announcement in April this year: Lu Yanbin, the current deputy director of the Strategic Project Management Office, will leave the company to seek external development opportunities due to personal reasons .
